Skip to content

Contact +44 (0) 20 7060 7474 email us

Bayer

Bayer Schering Pharma Ag

PharmaVitae Profile

Publication Date July 2008
Publisher Datamonitor
Product Type Report
Pages 183
ISBN Number not applicable
Product Code DAT01214

Price

£2,010.00
approximately: $2,995 | €2,205

pdf

Buy Now

print £2,045 ($3,048 | €2,243)

Buy Now

Order above formats by FAX

Order by Fax

Summary

Introduction

This analysis examines the historical and forecast performance for Bayer Schering Pharma in the ethical pharma sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information

Reasons to Purchase

  • Benchmark Bayer Schering Pharma's performance against key rivals in the ethical pharmaceutical sector
  • Analyse how Bayer's acquisition of Schering AG in 2006 has notably enhanced the healthcare focus as a proportion of its overall business
  • Assess how increased healthcare focus, merger-related synergies and other cost restructuring will drive a 12.2% CAGR in operating profit over 2007-13

Contents

  • CHAPTER 1 ABOUT THIS PROFILE
    • Executive summary
    • Quarterly news update
    • Company introduction
    • Company sales
    • Company financials
    • Key products and competitors
    • Data sourcing
    • Sales data
    • Analyst consensus
  • CHAPTER 2 EXECUTIVE SUMMARY
    • Key findings
    • Prescription pharmaceutical sales performance, 2001-13
    • Financial performance, 2001-13
    • Bayer AG: PharmaVitae forecasts at a glance
    • Strategic insight
    • Evolution towards a greater Rx pharma focus
    • 1) 2001-04: Rx pharma performance collapses due to Baycol withdrawal and Ciprobay sales decline
    • Blockbuster Baycol is withdrawn from the market
    • Blockbuster Ciprobay suffers genericization
    • 2) 2004-07: Corporate restructuring
    • 2004: Divestment of Lanxess AG
    • 2006-07: Acquisition of Schering AG
    • 2007: Divestment of MaterialScience subsidiaries
    • 3) 2007-13: Bayer portfolio drives forecast sales growth and cost savings are implemented
    • Cost cutting initiatives to increase operating profit
    • Bayer's Rx portfolio drives growth
    • A new era for Bayer Schering Pharma
    • SWOT analysis
    • Strengths
    • Weaknesses
    • Opportunities
    • Threats
  • CHAPTER 3 QUARTERLY NEWS UPDATE
    • Product developments
    • Deals and alliances
    • Product deals
    • Technology deals
    • M&A activity
    • Company announcements
    • Future product milestones
  • CHAPTER 4 COMPANY INTRODUCTION
    • Key findings
    • Company overview
    • Company history
    • Current corporate structure
    • Bayer HealthCare
    • Bayer MaterialScience
    • Bayer CropScience
    • M&A history
    • Acquisition of Roche Consumer Health AG (RCH)
    • Lanxess AG Spin-off
    • Divestment of US Plasma Products
    • Acquisition of Schering AG
    • Recent M&A promotes Bayer's healthcare focus
    • Divestment of Diagnostics Division
    • Divestment of HC Starck and Wolff Walsrode
    • Acquisition of Possis Medical and Sagmel Inc
    • M&A strategy
  • CHAPTER 5 COMPANY SALES ANALYSIS
    • Key findings
    • Prescription pharmaceutical sales and growth rate analysis, 2001-13
    • Product analysis
    • Product analysis, 2001-07
    • Product analysis, 2007-13
    • Therapy area analysis
    • Therapy area analysis, 2001-07
    • Therapy area analysis, 2007-13
    • Therapy area focus, 2001-13
    • Geographic analysis
    • Geographic analysis, 2001-07
    • Geographic analysis, 2007-13
    • Geographic focus, 2001-13
    • Launch/core/expiry analysis
    • Explanation of launch/core/expiry analysis
    • Launch analysis, 2007-13
    • Core analysis, 2007-13
    • Expiry analysis, 2007-13
    • Launch/core/expiry configuration, 2007-13
    • Molecule type analysis
    • Molecule type analysis, 2001-07
    • Molecule type analysis, 2007-13
    • Externalization analysis
    • Externalization analysis, 2001-07
    • Externalization analysis, 2007-13
  • CHAPTER 6 COMPANY FINANCIALS
    • Key findings
    • Reconciliation between PharmaVitae-formatted prescription pharma revenue and Bayer AG-reported total revenue, 2001-07
    • Financial statements, 2001-07
    • Profit and loss account, 2001-07
    • Balance sheet, 2001-07
    • Operating costs and profit analysis
    • Operating costs and profit analysis, 2001-07
    • Operating cost ratio and profit margin analysis, 2001-07
    • Operating cost ratio and profit margin analysis, 2007-13
    • Operating cost ratio and profit margin analysis, 2001-13
    • Operating costs and profit analysis, 2007-13
    • Return on capital employed analysis
    • Capital employed analysis, 2001-07
    • Return on capital employed (RoCE) analysis, 2001-07
    • Market capitalization analysis
    • Market capitalization analysis, 2001-07
    • Total shareholder returns (TSR) analysis, 2001-07
  • CHAPTER 7 KEY PRODUCTS AND COMPETITORS
    • Key findings
    • Overview
    • Hematology
    • Kogenate
    • Overview
    • Sales forecast
    • PEGylated formulation set to drive sales from 2011
    • Delivery device is key contributor to growth of Kogenate franchise
    • Growth of hemophilia market will continue to drive Kogenate sales growth
    • Key competitors
    • Patent challenge
    • Xarelto
    • Overview
    • Sales forecast
    • A replacement for Warfarin?
    • Pradaxa expected to take first-to-market advantage
    • Positive Phase III trial data buoys sales hopes
    • Urology and gender-specific health
    • Mirena
    • Overview
    • Sales forecast
    • An alternative to sterilization
    • Launch in the Japanese market
    • Key competitors
    • Levitra
    • Overview
    • Sales forecast
    • Key competitors
    • PDE-5 safety concerns
    • Levitra licensing agreements
    • Yasmin
    • Overview
    • Sales forecast
    • Yasmin: a historical growth driver
    • Yasmin patent invalidated following challenge from Barr Pharmaceuticals
    • The impact of generics
    • Key competitors
    • Yaz
    • Overview
    • Sales forecast
    • The Impact of Yasmin's invalidated patent protection
    • New market launches
    • Key competitors
    • The switch from Yasmin to Yaz
    • Oncology
    • Nexavar
    • Overview
    • Sales forecast
    • Nexavar encounters strong competition in the RCC market
    • HCC market to offer better sales potential
    • Further indication broadening will boost sales growth
    • Leukine
    • Overview
    • Sales forecast
    • Ongoing development to expand Leukine's range of indications
    • Leukine sales limited to the competitive US market
    • Safety concerns
    • Central nervous system
    • Betaferon
    • Overview
    • Sales forecast
    • Betaferon: a success story despite initial challenges
    • Novartis agreement
    • Key competitors
    • The Tysabri withdrawal
    • Infectious disease
    • Avelox
    • Overview
    • Sales forecast
    • Antibiotics market encounters growing patient resistance
    • Key competitors
    • Avelox in a good position despite increasing genericization
    • Avelox patent challenge: generic moxifloxacin not expected by 2013
    • Ciprobay
    • Overview
    • Sales forecast
    • Rapid genericization in forecast period
    • A key historical growth driver
    • The problem of resistance
    • Life cycle management
    • Cardiovascular
    • Adalat
    • Overview
    • Sales forecast
    • Extended release formulation rejuvenates brand
    • The impact of genericization
    • Rise of the ARB class
    • Endocrinology and other metabolic disorders
    • Glucobay
    • Overview
    • Sales forecast
    • The poor performance of the AGI class
    • Key competitors
  • CHAPTER 8 APPENDIX
    • R&D pipeline
    • New molecular entity pipeline
    • Indication broadening pipeline
    • References
    • Abbreviations
    • Exchange rates
  • List of Tables
    • Table 1: Bayer AG- PharmaVitae forecasts at a glance
    • Table 2: Bayer Schering Pharma AG key product developments, Q1 2008
    • Table 3: Bayer Schering Pharma AG product deals and alliances, Q1 2008
    • Table 4: Bayer Schering Pharma AG technology deals and alliances, Q1 2008
    • Table 5: Bayer HealthCare M&A activity, Q1 2008
    • Table 6: Bayer AG company announcements, Q1 2008
    • Table 7: Bayer Schering Pharma future product milestones, Q2 2008-Q1 2010
    • Table 8: Bayer Schering Pharma product portfolio overview, sales ($m), 2001-07
    • Table 9: Bayer Schering Pharma product portfolio overview, global sales ($m), 2007-13
    • Table 10: Bayer Schering Pharma therapy portfolio overview, sales ($m), 2001-07
    • Table 11: Bayer Schering Pharma therapy portfolio overview, sales ($m), 2007-13
    • Table 12: Bayer Schering Pharma portfolio overview by geographic region, sales ($m), 2001-07
    • Table 13: Bayer Schering Pharma portfolio overview by geographic region, sales ($m), 2007-13
    • Table 14: Bayer Schering Pharma launch portfolio overview ($m), 2007-13
    • Table 15: Bayer Schering Pharma core portfolio overview ($m), 2007-13
    • Table 16: Bayer Schering Pharma expiry portfolio overview ($m), 2007-13
    • Table 17: Bayer Schering Pharma portfolio overview by molecule type ($m), 2001-07
    • Table 18: Bayer Schering Pharma product portfolio overview by molecule type ($m), 2007-13
    • Table 19: Bayer Schering Pharma product portfolio overview by source ($m), 2001-07
    • Table 20: Bayer Schering Pharma AG product portfolio overview by source ($m), 2007-13
    • Table 21: Total Bayer AG revenue by business unit ($m), 2001-07
    • Table 22: Bayer AG profit and loss account ($m), 2001-07
    • Table 23: Bayer AG balance sheet ($m), 2001-07
    • Table 24: Bayer AG operating revenue/cost analysis ($m), 2001-07
    • Table 25: Bayer AG operating cost ratio analysis (% of total revenue), 2001-07
    • Table 26: Bayer AG operating cost ratio analysis (% of total revenue), 2007-13
    • Table 27: Bayer AG operating revenue/cost analysis ($m), 2007-13
    • Table 28: Bayer AG capital employed ($m), 2001-07
    • Table 29: Bayer AG EBIT return on capital employed ($m), 2001-07
    • Table 30: Bayer AG EBIT pre-tax return/Capital employed driver analysis ($m), 2001-07
    • Table 31: Bayer AG market capitalization ($ billion), 2001-07
    • Table 32: Bayer AG total shareholder returns, 2001-07 (annual %)
    • Table 33: Bayer Schering Pharma: Key products overview
    • Table 34: Kogenate: overview
    • Table 35: Kogenate: sales forecast ($m), 2007-13
    • Table 36: Xarelto: overview
    • Table 37: Xarelto: sales forecast ($m), 2007-13
    • Table 38: Mirena: overview
    • Table 39: Mirena: sales forecast ($m), 2007-13
    • Table 40: Key players in the oral contraceptives market, 2001-13
    • Table 41: Levitra: overview
    • Table 42: Levitra: sales forecast ($m), 2007-13
    • Table 43: Yasmin: overview
    • Table 44: Yasmin: sales forecast ($m), 2007-13
    • Table 45: Key players in the oral contraceptives market, 2007-13
    • Table 46: Yaz: overview
    • Table 47: Yaz: sales forecast ($m), 2007-13
    • Table 48: Nexavar: overview
    • Table 49: Nexavar: sales forecast ($m), 2007-13
    • Table 50: Leukine: overview
    • Table 51: Leukine: sales forecast ($m), 2007-13
    • Table 52: Betaferon: overview
    • Table 53: Betaferon: sales forecast ($m), 2007-13
    • Table 54: Avelox: overview
    • Table 55: Avelox: sales forecast ($m), 2007-13
    • Table 56: Key players in the antibiotics market, 2007
    • Table 57: Ciprobay: overview
    • Table 58: Ciprobay: sales forecast ($m), 2007-13
    • Table 59: Adalat: overview
    • Table 60: Adalat: sales forecast ($m), 2007-13
    • Table 61: Glucobay: overview
    • Table 62: Glucobay: sales forecast ($m), 2007-13
    • Table 63: Bayer Schering Pharma AG's NME pipeline (Phase I-registration)
    • Table 64: Bayer Schering Pharma AG's indication broadening pipeline (Phase I-registration)
    • Table 65: Exchange rates, 2007
  • List of Figures
    • Figure 1: Bayer AG prescription pharmaceutical performance, sales ($m) and growth rate (%), 2001-13
    • Figure 2: Bayer AG financial performance ($m), 2001-13
    • Figure 3: Bayer AG corporate development, 2001-13
    • Figure 4: Bayer Schering Pharma prescription pharmaceutical sales by source ($m), 2007-13
    • Figure 5: Bayer Schering Pharma prescription pharmaceutical sales by therapy area ($m), 2001-13
    • Figure 6: Bayer Schering Pharma SWOT analysis
    • Figure 7: Current corporate structure
    • Figure 8: M&A/divestment history Bayer AG
    • Figure 9: Bayer Schering Pharma prescription pharmaceutical performance, sales ($m) and growth rate (%), 2001-13
    • Figure 10: Bayer Schering Pharma key sales growth drivers and resistors ($m), 2001-07
    • Figure 11: Bayer Schering Pharma key sales growth drivers and resistors ($m), 2007-13
    • Figure 12: Bayer Schering Pharma prescription pharmaceutical sales by therapy area ($m), 2001-13
    • Figure 13: Bayer Schering Pharma prescription pharma sales by therapy area, (% of total), 2001-13
    • Figure 14: Bayer Schering Pharma prescription pharmaceutical sales by geographic region ($m), 2001-13
    • Figure 15: Bayer Schering Pharma drivers and resistors by geographic region, sales ($m), 2001-07
    • Figure 16: Bayer Schering Pharma drivers and resistors by geographic region, sales ($m), 2007-13
    • Figure 17: Bayer Schering Pharma prescription pharmaceutical sales by geographic region (% of total), 2001-13
    • Figure 18: Bayer Schering Pharma launch/core/expiry configuration ($m), 2007-13
    • Figure 19: Bayer Schering Pharma prescription pharmaceutical sales by molecule type ($m), 2001-13
    • Figure 20: Bayer Schering Pharma growth drivers & resistors by molecule type ($m), 2007-13
    • Figure 21: Bayer Schering Pharma prescription pharmaceutical sales by source ($m), 2001-13
    • Figure 22: Bayer Schering Pharma growth drivers & resistors by source ($m), 2001-07
    • Figure 23: Bayer Schering Pharma growth drivers & resistors by source ($m), 2007-13
    • Figure 24: Bayer AG operating revenue/cost analysis ($m), 2001-13
    • Figure 25: Bayer AG operating cost ratio analysis (% of total revenue), 2001-13
    • Figure 26: Bayer AG return on capital employed, EBIT margin and capital turnover, 2001-07
    • Figure 27: Return on capital employed formula
    • Figure 28: Bayer AG market capitalization ($ billion), 2001-07
    • Figure 29: Bayer AG total shareholder returns (annual %), 2001-07